Johnson & Johnson Receives FDA Approval for TRUFILL n‑BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma

2i2 The approval is supported by findings from the MEMBRANE randomized controlled trial, which evaluated the safety and effectiveness of MMA embolization in patients with cSDH. The results of the MEMBRANE study demonstrated that TRUFILL n-BCA is superior in effectiveness compared to Standard of Care (SOC) for embolization in the MMA for the treatment of symptomatic cSDH, and importantly, TRUFILL n-BCA was demonstrated to be safe for treating cSDH. "This approval reinforces the enduring value of TRUFILL n-BC ...